MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze LLY →
    • FindStock Picks / Stock Screener
    • Value · LLYIntrinsic Value Calculator
    • Invest · LLYInvestment Case
    • Hold · LLY5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
LLY stock logo

LLY

Eli Lilly and Company

$1443.5
17.95
 (1.26%)
Exchange:  NYSE
Market Cap:  1.358T
Shares Outstanding:  898.002M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – GeneralView industry performance
   
CEO:  David A. Ricks
Full Time Employees:  50000
Address: 
Lilly Corporate Center
Indianapolis
IN
46285
US
Website:  https://www.lilly.com
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin’s lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

LLY full analysis

31/10/2026

Welcome back to MarketSnap. Let me start with something uncomfortable, because I think we've earned it. Back in February, when Lilly became the first pharma company ever to cross a trillion dollars, we looked at it and said: wonderful business, fairly valued around where it traded, but don't chase it — wait for a ten to fifteen percent pullback. That pullback never came. The stock is up about thirty-four percent since that video, it's sitting around fourteen hundred dollars a…

Listen to full analysis (audio file)

Open in MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
LLLLY logoLLYEli Lilly and Company1.36T46.740.830.5%
JNJNJ logoJNJJohnson & Johnson687.9B43.325.715.0%
ABABBV logoABBVAbbVie Inc.521.5B50.621.116.6%
MRMRK logoMRKMerck & Co., Inc.364.3B14953.24.4%
NVNVS logoNVSNovartis AG303.1B30.818.014.0%
AZAZN logoAZNAstraZeneca PLC286.1B25.918.013.1%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/10/29 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue34,124,10045,043,00065,179,000
Gross Profit27,041,90036,625,00054,127,000
EBITDA8,567,80018,807,00031,693,000
Operating Income10,787,30017,040,00029,696,000
Net Income5,240,40010,590,00020,640,000

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets64,006,30078,714,900112,476,000
Total Liabilities53,142,60064,443,30085,941,000
Total Stockholders Equity10,771,90014,192,10026,535,000
Total Debt25,225,30033,644,20042,503,000
Cash and Cash Equivalents2,818,6003,268,4007,268,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow4,240,1008,817,90016,813,000
Capital Expenditure-7,392,100-8,403,600-7,841,000
Free Cash Flow-3,152,000414,3008,972,000
Net Income5,240,40010,590,00020,640,000
Net Change in Cash751,600449,8004,000,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)131,284,821.259Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)148,671,954.588Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)141,406,079.175Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)79,733,927.188Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)92,065,618.902Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)86,912,353.681Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)59,628,518.229Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)70,137,808.706Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)65,746,102.980Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)26,708,128.780Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)30,245,306.892Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)28,767,162.393Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)73.210Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)78.100Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)66.400Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)12Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
45.043B  ?P/S
 (TTM)
: 
15.71
?Net Income
 (TTM)
: 
10.59B  ?P/E
 (TTM)
: 
46.73
?Enterprise Value
 (TTM)
: 
1.403T  ?EV/FCF
 (TTM)
: 
71.34
?Dividend Yield
 (TTM)
: 
0.48%  ?Payout Ratio
 (TTM)
: 
21.68%
?ROE
 (TTM)
: 
83.65%  ?ROIC
 (TTM)
: 
30.5%
?Net Debt
 (TTM)
: 
30.221B  ?Debt/Equity
 (TTM)
: 
1.23
?P/B
 (TTM)
: 
31.97  ?Current Ratio
 (TTM)
: 
1.39

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
40.81Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

Strengths (preview)

  • Exceptional top-line momentum: Q3 2026 revenue grew 39% year-over-year, with FY2026 guidance raised by $5.5B to $91–92B; FY2025 revenue of $65.2B and net income of $20.6B represent roughly 45% and 95% growth over FY2024, respectively, driven by Mounjaro and Zepbound.
  • Best-in-class profitability: TTM gross margin of 83.4%, net margin of 33.5%, ROE of 92.6%, and ROIC of 31.0%, with gross margin improving further to 84.4% in Q3 2026.
  • Diversifying revenue base: oncology, immunology, and neuroscience portfolios contributed over $6B in key product revenue growth, reducing reliance on incretins; international markets (Europe $11.6B, non-US $6.1B in FY2025) provide geographic breadth.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Research Access for the complete SWOT analysis.

Create a free account

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates LLY intrinsic value between $715.74 – $978.28 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate LLY Intrinsic Value

Common questions about LLY valuation

Is Eli Lilly and Company (LLY) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Eli Lilly and Company (LLY) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is LLY a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether LLY trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is LLY’s P/E ratio?

You can see LLY’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for LLY?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is LLY a good long-term investment?

Whether LLY fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Eli Lilly and Company

  • Eli Lilly and Company intrinsic value calculatorEstimate what the business is worth
  • Eli Lilly and Company 5-year outlookWhat has to go right, and what could go wrong
LLY

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

1.26
MarketSnap

Trading Metrics:

Open: 1429.91   Previous Close: 1425.55
Day Low: 1419.81   Day High: 1449.64
Year Low: 850.51   Year High: 1460
Price Avg 50: 1235.4   Price Avg 200: 1107.23
Volume: 1.872M   Average Volume: 2.588M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Mapping the Market: Eli Lilly shares ready to rally again
13-11-2026 06:10
Mapping the Market: Eli Lilly shares ready to rally again
Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It
12-11-2026 13:16
Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It
China approves Eli Lilly's weight loss pill orforglipron
12-11-2026 02:22
China approves Eli Lilly's weight loss pill orforglipron
EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat
11-11-2026 09:56
EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoria
11-11-2026 09:45
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoria
Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence
06-11-2026 19:18
Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze LLY →
    • FindStock Picks / Stock Screener
    • Value · LLYIntrinsic Value Calculator
    • Invest · LLYInvestment Case
    • Hold · LLY5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.